GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70200 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Helen Tesfaye und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Optic Neuropathy, Ischemic, Sodium-Glucose Transporter 2 Inhibitors, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, NIAMS NIH HHS, FDA HHS.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims
Evidence on the safety of semaglutide and other glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) concerning non‐arteritic anterior ischemic optic neuropathy (NAION) is inconclusive, with several studies published to date presenting methodological challenges. We sought to compare the risk of presumed NAION in patients with type 2 diabetes (T2D), initiating a GLP‐1RA versus a sodium‐glucose cotransporter‐2 inhibitor (SGLT2i), using a new‐user active comparator cohort study design within a target trial emulation framework. Materials and methods Using insurance claims data from three databases (01/2016–08/2024), we identified 482 912 propensity score matched (1:1) pairs of GLP‐1RA and SGLT2i adult initiators with T2D and without prior ischemic optic neuropathy (ION) or other optic nerve disorders. NAION was defined as a diagnosis of ION without other causes of optic neuropathy, combined with an ophthalmologist or optometrist visit on the same day. We estimated pooled hazard ratios (HRs) and rate differences (RDs).
Results
Over a median follow‐up of 6.7 months on treatment, the risk of incident NAION was higher among initiators of GLP‐1RA compared with SGLT2i [HR, 1.85; 95% CI (1.51–2.27); RD, 0.29 (0.19, 0.39) per 1000 person‐years]. Results were consistent across subgroups and sensitivity analyses. A meta‐analysis of our semaglutide analysis with previously published results also showed an elevated risk, with a HR of 2.78 (1.39–5.56).
Conclusions
In this large observational study, the initiation of GLP‐1RA was associated with an 85% increase in the risk of presumed NAION, compared with the initiation of SGLT2is, though incidence rates and absolute increase in risk were small.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoepidemiology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, Massachusetts, USA.
- MGH Diabetes Center, Division of Endocrinology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Department of Ophthalmology, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Neuro-Ophthalmology Service, Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, USA.
- Endocrine Unit, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
ORCID-Profile: Helen Tesfaye, Elisabetta Patorno
Förderung
- NIDDK NIH HHS
- NIAMS NIH HHS
- FDA HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Tesfaye, H., Paik, J. M., Wexler, D. J., Hathaway, J. T., Yu, E. W., Freedman, A., Rizzo, J. F., & Patorno, E. (2026). GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70200
Vancouver
Tesfaye H, Paik JM, Wexler DJ, Hathaway JT, Yu EW, Freedman A, et al. GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70200
BibTeX
@article{Tesfaye2026,
author = {Tesfaye, Helen and Paik, Julie M and Wexler, Deborah J and Hathaway, Jimena Tatiana and Yu, Elaine W and Freedman, Ariel and Rizzo, Joseph F and Patorno, Elisabetta},
title = {GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70200}
}
EUVIMED